Cytarabine

Generic Name: Cytarabine

Brand Names: Cytosar, Vyxeos

Drug Type: Small Molecule

Chemical Formula: C_₉H_₁₃N_₃O_₅

CAS Number: 147-94-4

Unique Ingredient Identifier: 04079A1RDZ

Background: A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)

Indication: For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.

Cytarabine is indicated in combination with daunorubicin for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.

Associated Conditions: Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia

Associated Therapies: -

Clinical Trials

MLN 9708 in Induction and Consolidation for Adults With AML >= 60 Years of Age

Phase 1

Completed

Conditions: Acute Myeloid Leukemia

Interventions: Drug: MLN9708
Drug: Cytarabine
Drug: Daunorubicin

First Posted Date: 2015-10-21

Last Posted Date: 2022-08-24

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 39

Registration Number: NCT02582359

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Selinexor With Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia

Phase 1

Completed

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Cytarabine
Drug: Mitoxantrone Hydrochloride
Drug: Selinexor

First Posted Date: 2015-10-09

Last Posted Date: 2020-04-08

Lead Sponsor: University of Chicago

Target Recruit Count: 25

Registration Number: NCT02573363

Locations: 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML

Phase 2

Completed

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Alisertib
Drug: Cytarabine
Drug: Idarubicin
Drug: Daunorubicin

First Posted Date: 2015-09-25

Last Posted Date: 2020-05-05

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 42

Registration Number: NCT02560025

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I

Phase 1

Active, not recruiting

Conditions: Acute Lymphoblastic Leukemia

Interventions: Drug: ITMHA
Drug: Dexamethasone
Drug: Mitoxantrone
Drug: Pegaspargase
Drug: Asparaginase Erwinia Chrysanthemi
Drug: Bortezomib
Drug: Vorinostat
Drug: Cyclophosphamide
Drug: Mercaptopurine
Drug: Methotrexate
Drug: Leucovorin Calcium
Drug: Cytarabine
Drug: Etoposide
Drug: Vincristine

First Posted Date: 2015-09-17

Last Posted Date: 2024-01-18

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 50

Registration Number: NCT02553460

Locations: 🇺🇸
Children's Hospital of Orange County, Orange, California, United States
🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
Rady Children's Hospital and Health Center, San Diego, California, United States

and more 14 locations

A Study of Idasanutlin With Cytarabine Versus Cytarabine Plus Placebo in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Phase 3

Terminated

Conditions: Leukemia, Myeloid, Acute

Interventions: Drug: Cytarabine
Other: Placebo
Drug: Idasanutlin

First Posted Date: 2015-09-09

Last Posted Date: 2022-01-11

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 447

Registration Number: NCT02545283

Locations: 🇫🇷
Hopital Claude Huriez; Hematologie, Lille, France
🇫🇷
Institut J Paoli I Calmettes; Onco Hematologie 2, Marseille, France
🇫🇷
Hopital Saint Louis; Oncologie Medicale, Paris, France

and more 79 locations

Pacritinib Combined With Decitabine or Cytarabine in Older Patients With AML

Phase 2

Terminated

Conditions: Acute Myeloid Leukemia (AML)

Interventions: Drug: Pacritinib
Drug: Decitabine
Drug: Cytarabine

First Posted Date: 2015-08-25

Last Posted Date: 2018-06-15

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 13

Registration Number: NCT02532010

Locations: 🇺🇸
Weill Cornell Medical College, New York, New York, United States

A Phase Ib Study of Belinostat With RDHAP Chemotherapy (Dexamethasone, Cytarabine, Cisplatinum) in Adults With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Phase 1

Withdrawn

Conditions: Lymphoma

Interventions: Drug: Belinostat
Drug: Rituximab
Drug: Cisplatin
Drug: Cytarabine
Drug: Dexamethasone
Drug: Ciprofloxacin
Drug: Fluconazole

First Posted Date: 2015-08-25

Last Posted Date: 2016-01-06

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT02532192

A Study of Volasertib Plus Induction Chemotherapy for Acute Myeloid Leukemia

Phase 1

Withdrawn

Conditions: Leukemia, Myelomonocytic, Acute
Leukemia, Myeloid, Acute
Leukemia, Monocytic, Acute
Leukemia, Erythroblastic, Acute
Leukemia, Megakaryoblastic, Acute

Interventions: Drug: Volasertib
Drug: Idarubicin
Drug: Cytarabine

First Posted Date: 2015-08-18

Last Posted Date: 2017-04-05

Lead Sponsor: University of Alberta

Registration Number: NCT02527174

Locations: 🇨🇦
University of Alberta Hospital, Edmonton, Alberta, Canada
🇨🇦
Tom Baker Cancer Centre, Calgary, Alberta, Canada

Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

Phase 2

Completed

Conditions: Acute,Leukemia, Lymphoid

Interventions: Drug: Dasatinib
Drug: prednisone
Drug: cyclophosphamide
Drug: daunorubicin
Drug: vincristine
Drug: cytarabine
Drug: mercaptopurine
Drug: methotrexate
Drug: dexamethasone
Drug: mitoxantrone
Drug: etoposide
Procedure: allogeneic hematopoietic stem cell transplantation
Procedure: autologous hematopoietic stem cell transplantation

First Posted Date: 2015-08-14

Last Posted Date: 2022-08-03

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 30

Registration Number: NCT02523976

Locations: 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China

Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome

Phase 3

Active, not recruiting

Conditions: Acute Myeloid Leukemia
Down Syndrome
Myelodysplastic Syndrome
Myeloid Leukemia Associated With Down Syndrome
Myeloproliferative Neoplasm

Interventions: Drug: Cytarabine
Drug: Asparaginase
Drug: Asparaginase Erwinia chrysanthemi
Drug: Daunorubicin Hydrochloride
Drug: Etoposide
Other: Laboratory Biomarker Analysis
Drug: Mitoxantrone Hydrochloride
Drug: Thioguanine

First Posted Date: 2015-08-13

Last Posted Date: 2024-11-07

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 280

Registration Number: NCT02521493

Locations: 🇨🇦
CHU de Quebec-Centre Hospitalier de l'Universite Laval (CHUL), Quebec, Canada
🇳🇿
Starship Children's Hospital, Grafton, Auckland, New Zealand
🇳🇿
Christchurch Hospital, Christchurch, New Zealand

and more 188 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy